Skip to main content

Application of RNA nanotechnology for delivery of mRNA therapeutics

Project description

Safe and effective RNA-based therapy may soon be homing in on cancer cells

Genetic information 'flows' from DNA through RNA to proteins. As the intermediary between the genetic code and the product, RNA and associated targets have tremendous therapeutic potential to control gene expression. The types of RNA and their roles continue to expand, and RNA-based therapies are growing. Small interfering RNA, or siRNA, are small pieces of double-stranded RNA that can interfere with protein translation by binding to mRNA and causing its degradation. Sixfold Bioscience has patented nanotechnology that can deliver siRNA to specific cells in the body with demonstrated biocompatibility and specificity. With EU support, the NanoDeli project enables Sixfold’s researchers to extend the application of the company’s proprietary delivery systems to diseases that were previously thought to be untreatable.

Call for proposal

H2020-INNOSUP-2018-2020

See other projects for this call

Sub call

H2020-INNOSUP-2019-02

Coordinator

SIXFOLD BIOSCIENCE LTD
Net EU contribution
€ 89 742,50
Address
The Imperial College White City Inc Innovation Hub
W12 0BZ London
United Kingdom

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00